RxDoctor Payments Data

Amer Husseini, MD

Cardiovascular Disease · Chicago, ILNPI 1578544664

Payments from drug & device makers

$1,203in general payments, 2019–2025

Across 61 payments — averaging $19.73 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Boehringer Ingelheim$406
  • Novartis$250
  • Merck$121
  • AstraZeneca$101
  • Novo Nordisk$93
  • E.r. Squibb & Sons, L.L.C.$87
  • plus $146 from 6 others

What the payments were for

  • Food & beverage$1,203100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$1,203 in reported general payments places this provider in the 40th percentile of 932 cardiovascular disease providers in Illinois.

See all cardiovascular disease providers in Illinois

Medicare billing

Part B allowed, 2024
$156,989
Medicare patients
362
Services billed
1,898

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban440$477,063
JardianceEmpagliflozin267$266,216
OzempicSemaglutide72$93,005
XareltoRivaroxaban68$86,274
EntrestoSacubitril/Valsartan56$66,338
TrulicityDulaglutide23$35,272
FarxigaDapagliflozin Propanediol39$35,117
JanuviaSitagliptin Phosphate21$26,144
MounjaroTirzepatide23$23,162
LinzessLinaclotide23$17,858
Metoprolol Succinate649$8,682
Albuterol Sulfate HfaAlbuterol Sulfate180$7,481
Repatha SyringeEvolocumab11$6,210
Rosuvastatin Calcium378$5,978
Losartan-HydrochlorothiazideLosartan/Hydrochlorothiazide306$5,260

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Boehringer IngelheimJardiance$406$266,216267 claims
Novo NordiskOzempic$93$93,00572 claims
NovartisEntresto$250$66,33856 claims
Lilly USA, LLCTrulicity, Mounjaro$23$58,43546 claims
AstraZenecaFarxiga$101$35,11739 claims
MerckJanuvia$121$26,14421 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 40th percentile of 932 cardiovascular disease providers in Illinois.

Other cardiovascular disease in Chicago

See the full list for Illinois

Where these figures come from

Is this you, or does something look wrong? →